Sprimeo HCT (aliskiren;hydrochlorothiazide)
- Region
- 🇪🇺 EU
- Active substance
- aliskiren;hydrochlorothiazide
- Company
- Novartis Europharm Ltd.
- Status
- Withdrawn
- Therapeutic area
- Hypertension
- EU approval
- Thu 23 Jun 2011
- Application
- EMEA/H/C/002421
- ATC
- C09XA52
- Official record
- www.ema.europa.eu
Indication
Treatment of essential hypertension in adults. Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Rasilez HCT Withdrawn · Noden Pharma DAC
- 🇪🇺 Riprazo HCT Withdrawn · Novartis Europharm Ltd.
Follow Sprimeo HCT
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.